Latest discovery! What are the neutralizing antibodies that vaccines are a global treasure that are constantly being developed?

The textSpeaking at the opening ceremony of the video conference at the 73rd WORLD Health Assembly, President Xi Jinping of theannounced that China will make China's contribution to achieving the accessibility and affordability of vaccines in developing countries when the research and development of China's new crown vaccine is completed and put into use as a global public productConhino's recombinant vaccine (adenovirus vector vaccine) is in the first echelon of global vaccine development, has been approved by Health Canada on recombinant vaccine (adenovirus vector) "Ad5-nCoV" clinical trialalso, the same as the first team of vaccine research and development of moderna's mRNA vaccine, also recently ushered in a breakthrough18, Moderna released early human trial data for its new coronarna vaccine mRNA-1273: 45 subjects all produced antibodies, the first 8 produced neutralizing antibodies, the minimum dose (25 micrograms) group on the 43rd day of the trial with the antibody level of the patients recovered from the virus, while the 100 microgram group "significantly exceeded this level", and there were no serious adverse reactions in the trialThe maximum dose of 250 micrograms will not be used in future clinical trials because volunteers have severe injection point allergies and systemic reactionsmRNA-1273 was developed by the National Institute of Allergy and Infectious Diseases (NIAID) and biotech company ModernaThe vaccine does not contain coronaviruses, but instead focuses on mRNA, instructing the body to produce proteins similar to the surface of the new coronavirus, in order to trigger an immune response while preventing infectionmRNA vaccine compared to traditional vaccines, the biggest advantage is speed, in addition, also do not need to attach adjuvant, good safety, production process is relatively convenient, can be mass-produced, Sanofi, Fosun Medicine and so on in the field of mRNA vaccine have layoutOn May 18, the American journal Science published an online paper entitled "A combination of a non-competitive human-derived neutral izing antibody that blocks THE COVID-19 virus and its receptor ACE2" said they had found two human-derived monoclonal antibodies that could effectively block neo-coronavirus infection, which are expected to be used in the development of anti-new coronadrugs and vaccinesThe topic of a out, that is, rushed Baidu hot search top!in the research and development of neutralizing antibodies for the new coronavirus, there are also many enterprises in China through independent research and development or cooperative research and development of the way to carry out researchBeijing scientific research of the Golden Triangle (Tsinghua, Peking University and the Chinese Academy of Sciences) also cooperation with enterprises, the Chinese Academy of Sciences and Junshi biological cooperation, Tsinghua University and Tengsheng Bo drug cooperation, Peking University and Yiyuan Shenzhou / Pharmaceutical Biology cooperation in a short period of time to develop therapeutic candidate antibodiesIn addition, Jimin credibility, Cinda Bio, Chengdu Shengshi Junlian, etcare also in their own platform to carry out research and developmentbefore that, Sorrento Therapeutics, an innovative drug company founded by the Chinese, announced that it had found an antibody that could block the binding of new coronaviruses to cells and had been shown to be 100% effective in the lab 100% effective, whether it is stock price speculation or indeed, wait for the article after the official publication of the data disclosure studies have shown that the new coronavirus is an RNA virus with a protrusion-like S-protein in its shell When the new coronavirus invades the cell, the S protein binds to the surface receptor ACE2 of the human cell, then enters the cell, is copied within the cell by transcription assasis, reassembles into a large number of new viruses, and continues to infect other cells, thus attacking the human body simple, to prevent virus cell replication, you need a substance can block the virus and cell surface receptor binding, said the bad point is to the virus to find another object, this "object" first with the virus, so that cells, and then can not infect cells, harm the human body This "object" is what we call neutralizing antibodies The serum (pulp) therapy used in the fight against new coronary pneumonia in China is essentially an antibody therapy note that neutralizing antibodies is not a vaccine, the vaccine is the use of antigens (bacteria/virus) to stimulate human cells, induce human cells to produce antibodies, and neutralizing antibody treatment is direct injection to begin to play a role , high-quality neutralizing antibodies can be used for the treatment of new coronary pneumonia, safer and more targeted, and can also be used for short-term prevention, even if the outbreak continues and recurs, the drug-like neutralizing antibodies are more effective than plasma therapy.